Hepatitis Monthly

Published by: Kowsar

LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes

Yuan Liu 1 , * , Ziying Zou 1 , Bing Zhu 1 , Zonghai Hu 1 , Ping Zeng 2 and Lijuan Wu 3
Authors Information
1 Department of Microbiology and Immunology, Laboratory Medicine Center, General Hospital of Chengdu Military Region of PLA, Chengdu, China
2 Department of Clinical Chemistry, Laboratory Medicine Center, General Hospital of Chengdu Military Region of PLA, Chengdu, China
3 Laboratory Medicine Center, General Hospital of Chengdu Military Region of PLA, Chengdu, China
Article information
  • Hepatitis Monthly: May 01, 2015, 15 (5); e28473
  • Published Online: May 23, 2015
  • Article Type: Research Article
  • Received: March 7, 2015
  • Revised: March 29, 2015
  • Accepted: April 11, 2015
  • DOI: 10.5812/hepatmon.15(5)2015.28473

To Cite: Liu Y, Zou Z, Zhu B, Hu Z, Zeng P, et al. LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes, Hepat Mon. 2015 ; 15(5):e28473. doi: 10.5812/hepatmon.15(5)2015.28473.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010; 8(11): 924-33[DOI][PubMed]
  • 2. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med. 2014; 7: 387-98[DOI][PubMed]
  • 3. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014; 108: 181-91[DOI][PubMed]
  • 4. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014; 109(5): 628-35[DOI][PubMed]
  • 5. Gunduz F, Mallikarjun C, Balart LA, Dash S. Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection. Exp Mol Pathol. 2014; 96(1): 36-41[DOI][PubMed]
  • 6. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol. 2005; 79(10): 6291-8[DOI][PubMed]
  • 7. Wang C, Pflugheber J, Sumpter RJ, Sodora DL, Hui D, Sen GC, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003; 77(7): 3898-912[PubMed]
  • 8. Guo JT, Sohn JA, Zhu Q, Seeger C. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology. 2004; 325(1): 71-81[DOI][PubMed]
  • 9. Pflugheber J, Fredericksen B, Sumpter RJ, Wang C, Ware F, Sodora DL, et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A. 2002; 99(7): 4650-5[DOI][PubMed]
  • 10. Liu YT, Yin HL. Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies. J Biol Chem. 1998; 273(14): 7920-7[PubMed]
  • 11. Choe N, Kwon JS, Kim JR, Eom GH, Kim Y, Nam KI, et al. The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis. 2013; 229(2): 348-55[DOI][PubMed]
  • 12. Wilson SA, Brown EC, Kingsman AJ, Kingsman SM. TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I. Nucleic Acids Res. 1998; 26(15): 3460-7[PubMed]
  • 13. Nguyen JB, Modis Y. Crystal structure of the dimeric coiled-coil domain of the cytosolic nucleic acid sensor LRRFIP1. J Struct Biol. 2013; 181(1): 82-8[DOI][PubMed]
  • 14. Bagashev A, Fitzgerald MC, Larosa DF, Rose PP, Cherry S, Johnson AC, et al. Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon response. J Interferon Cytokine Res. 2010; 30(11): 843-52[DOI][PubMed]
  • 15. Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol. 2010; 11(6): 487-94[DOI][PubMed]
  • 16. Sumpter RJ, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol. 2005; 79(5): 2689-99[DOI][PubMed]
  • 17. Liu Y, Zou Z, Zhu B, Hu Z, Zeng P. CXCL10 decreases GP73 expression in hepatoma cells at the early stage of hepatitis C virus (HCV) infection. Int J Mol Sci. 2013; 14(12): 24230-41[DOI][PubMed]
  • 18. Perales C, Beach NM, Sheldon J, Domingo E. Molecular basis of interferon resistance in hepatitis C virus. Curr Opin Virol. 2014; 8: 38-44[DOI][PubMed]
  • 19. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004; 5(7): 730-7[DOI][PubMed]
  • 20. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A. 2004; 101(49): 17264-9[DOI][PubMed]
  • 21. Suriano AR, Sanford AN, Kim N, Oh M, Kennedy S, Henderson MJ, et al. GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol Cell Biol. 2005; 25(20): 9073-81[DOI][PubMed]
  • 22. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003; 4(5): 491-6[DOI][PubMed]
  • 23. Weber F. Interaction of hepatitis C virus with the type I interferon system. World J Gastroenterol. 2007; 13(36): 4818-23[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments